Literature DB >> 26014717

Local Recurrence after Radiofrequency Ablation of Hepatocellular Carcinoma: Treatment Choice and Outcome.

Xiaoyan Xie1, Chunlin Jiang, Zhengwei Peng, Baoxian Liu, Wenjie Hu, Ye Wang, Manxia Lin, Mingde Lu, Ming Kuang.   

Abstract

BACKGROUND/AIMS: Radiofrequency ablation (RFA) has been proven effective for treating small hepatocellular carcinoma (HCC) nodules. However, post-RFA local recurrence is a major factor limiting prognosis. Up to now, there is no consensus on a standardized treatment strategy for these local recurrences. The aim of this study is to evaluate the outcomes of salvage treatments for RFA-related local recurrence.
METHODS: From May 2008 to June 2013, a total of 112 patients with HCC were detected with local recurrence after RFA. Among them, 94 patients received sequential treatments in our hospital, including salvage resection (SR) (n = 24), salvage liver transplantation (n = 2), repeated RFA (n = 62), and transarterial chemoembolization (TACE) (n = 6). We evaluated the treatment outcomes of patients by salvage surgery (SS), RFA, and TACE.
RESULTS: The median follow-up time was 32 months. After treatment, local recurrence was eradicated in 82 of 94 patients (87.2%). The complete response (CR) rate in the RFA group was 90.3% (56/62), while it was 100% (26/26) in the SS group (P = 0.175) and 0% (0/6) in the TACE group. When analysis confined to patients with CR, the 1- and 3-year disease-free survival (DFS) rates were 57.7 and 20.2% in the SS group, and 41.7 and 28.6% in the RFA group, respectively (P = 0.640). The 1- and 3-year overall survival (OS) rates were 93.3 and 69.1% in the SS group, and 78.6 and 57.5% in the RFA group, respectively (P = 0.251).
CONCLUSION: Repeated RFA is the first treatment choice for patients with post-RFA local recurrence. SS should be considered when RFA failed or is inapplicable.

Entities:  

Mesh:

Year:  2015        PMID: 26014717     DOI: 10.1007/s11605-015-2850-z

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  21 in total

Review 1.  Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors.

Authors:  Stefaan Mulier; Yicheng Ni; Jacques Jamart; Theo Ruers; Guy Marchal; Luc Michel
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

2.  Salvage hepatic resection after incomplete interstitial therapy for primary and secondary liver tumours.

Authors:  G Torzilli; D Del Fabbro; A Palmisano; M Marconi; M Makuuchi; M Montorsi
Journal:  Br J Surg       Date:  2007-02       Impact factor: 6.939

3.  Therapeutic results of computed-tomography-guided transcatheter arterial chemoembolization for local recurrence of hepatocellular carcinoma after initial transcatheter arterial chemoembolization: the results of 85 recurrent tumors in 35 patients.

Authors:  Mikio Tezuka; Keiji Hayashi; Yoichi Okada; Tetsuya Irie; Hiroyasu Ina
Journal:  Dig Dis Sci       Date:  2008-07-23       Impact factor: 3.199

4.  Salvage liver transplantation for recurrent hepatocellular carcinoma after radiofrequency ablation: a new strategy?

Authors:  Robin K Kelley; Francis Yao
Journal:  J Hepatol       Date:  2011-08-26       Impact factor: 25.083

5.  Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation?

Authors:  Albert C Y Chan; See Ching Chan; Kenneth S H Chok; Tan To Cheung; Dai Wing Chiu; Ronnie T P Poon; Sheung Tat Fan; Chung Mau Lo
Journal:  Liver Transpl       Date:  2013-03-17       Impact factor: 5.799

6.  Survival after radiofrequency ablation and salvage transplantation in patients with hepatocellular carcinoma and Child-Pugh A cirrhosis.

Authors:  Gisèle N'Kontchou; Mounir Aout; Alexis Laurent; Pierre Nahon; Nathalie Ganne-Carrié; Véronique Grando; Iman Baghad; Dominique Roulot; Jean Claude Trinchet; Nicolas Sellier; Daniel Cherqui; Eric Vicaut; Michel Beaugrand; Olivier Seror
Journal:  J Hepatol       Date:  2011-05-19       Impact factor: 25.083

7.  Clinicopathology of recurrent hepatocellular carcinomas after radiofrequency ablation treated with salvage surgery.

Authors:  Naoki Yamamoto; Keiichi Okano; Yoshio Kushida; Akihiro Deguchi; Shinichi Yachida; Yasuyuki Suzuki
Journal:  Hepatol Res       Date:  2013-09-18       Impact factor: 4.288

8.  Long-term outcome of percutaneous ablation in very early-stage hepatocellular carcinoma.

Authors:  Ming Kuang; Xiao-Yan Xie; Cheng Huang; Ye Wang; Man-Xia Lin; Zuo-Feng Xu; Guang-Jian Liu; Ming-De Lu
Journal:  J Gastrointest Surg       Date:  2011-10-05       Impact factor: 3.452

9.  Hepatectomy for recurrent colorectal liver metastases after radiofrequency ablation.

Authors:  A Brouquet; J-N Vauthey; B D Badgwell; E M Loyer; H Kaur; S A Curley; E K Abdalla
Journal:  Br J Surg       Date:  2011-05-03       Impact factor: 6.939

10.  Salvage treatment for local recurrence of hepatocellular carcinoma after local ablation therapy.

Authors:  Katsunori Imai; Toru Beppu; Akira Chikamoto; Kosuke Mima; Hirohisa Okabe; Hiromitsu Hayashi; Hidetoshi Nitta; Takatoshi Ishiko; Hideo Baba
Journal:  Hepatol Res       Date:  2014-03-18       Impact factor: 4.288

View more
  9 in total

Review 1.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2019-07       Impact factor: 3.500

2.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2019-05-15       Impact factor: 4.519

3.  All-trans retinoic acid (ATRA) inhibits insufficient radiofrequency ablation (IRFA)-induced enrichment of tumor-initiating cells in hepatocellular carcinoma.

Authors:  Song Wang; Jingtao Liu; Hao Wu; Anna Jiang; Kun Zhao; Kun Yan; Wei Wu; Haibo Han; Yanhua Zhang; Wei Yang
Journal:  Chin J Cancer Res       Date:  2021-12-31       Impact factor: 5.087

4.  Initial Incomplete Thermal Ablation Is Associated With a High Risk of Tumor Progression in Patients With Hepatocellular Carcinoma.

Authors:  Jie Tan; Tian Tang; Wei Zhao; Zi-Shu Zhang; Yu-Dong Xiao
Journal:  Front Oncol       Date:  2021-10-18       Impact factor: 6.244

5.  Safety and efficacy of pentazocine-midazolam combination for pain and anxiety relief in radiofrequency ablation therapy for hepatocellular carcinoma.

Authors:  Masanori Nakano; Yuichi Torisu; Chika Nakagawa; Kaoru Ueda; Tomoya Kanai; Chisato Saeki; Tsunekazu Oikawa; Masayuki Saruta
Journal:  JGH Open       Date:  2022-07-17

6.  Electric Ablation with Irreversible Electroporation (IRE) in Vital Hepatic Structures and Follow-up Investigation.

Authors:  Xinhua Chen; Zhigang Ren; Tongyin Zhu; Xiongxin Zhang; Zhiyi Peng; Haiyang Xie; Lin Zhou; Shengyong Yin; Junhui Sun; Shusen Zheng
Journal:  Sci Rep       Date:  2015-11-09       Impact factor: 4.379

7.  Impact of the Uridine⁻Cytidine Kinase Like-1 Protein and IL28B rs12979860 and rs8099917 SNPs on the Development of Hepatocellular Carcinoma in Cirrhotic Chronic Hepatitis C Patients-A Pilot Study.

Authors:  Arida Buivydiene; Valentina Liakina; Elena Kashuba; Jolita Norkuniene; Skirmante Jokubauskiene; Egle Gineikiene; Jonas Valantinas
Journal:  Medicina (Kaunas)       Date:  2018-09-27       Impact factor: 2.430

8.  Performance of LI-RADS version 2018 CT treatment response algorithm in tumor response evaluation and survival prediction of patients with single hepatocellular carcinoma after radiofrequency ablation.

Authors:  Yun Zhang; Jinju Wang; Hui Li; Tianying Zheng; Hanyu Jiang; Mou Li; Bin Song
Journal:  Ann Transl Med       Date:  2020-03

9.  Ultrasound-guided secondary radiofrequency ablation combined with chemotherapy in gastric cancer with recurrent liver metastasis.

Authors:  Xiaoxiang Fan; Yan Zhang; Meiwu Zhang; Dafeng Mao; Haitao Jiang
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.